CVAC
4.33 USD
+0.00%
Today
+0.00%
1D
Last seen at Wed, 25 Feb 2026 00:35:15 GMT+3
Market is closed
Sun
Closed
Mon
4:30 PM ~ 10:59 PM
Tue
4:30 PM ~ 10:59 PM
Wed
4:30 PM ~ 10:59 PM
Thu
Closed
Fri
4:30 PM ~ 10:59 PM
Sat
Closed
Information
Name
CureVac Leveraged
Currency
USD
Standard Leverage
1X
Enhanced Leverage
3X
Overnight Fees Buy
-0.0185%
Overnight Fees Sell
0.0018%
Market Cap
1.19B
Avg Daily Volume
525.85K
52 Week High
5.72 USD
52 Week Low
2.37 USD
Trading Hours
See hours
Overnight Fees Calculator
| Daily Overnight Fee % | Daily Overnight Fee $ | |
|---|---|---|
| BUYS | -0.01850% | $(0.185) |
| SELLS | 0.00180% | $0.018 |
*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.
Business Summary
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Top News
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
tradingview.com
6mo ago
CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech
tradingview.com
6mo ago
CureVac Announces Voting Results of General Meeting
tradingview.com
8mo ago
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.
